

Pooled analysis of diarrhea events in patients with cancer treated with lapatinib

John P. Crown · Harold A. Burris III · Fran Boyle · Suzanne Jones · Maria Koehler ·
Beth O. Newstat · Roma Parikh · Cristina Oliva · Alaknanda Preston · Julie Byrne ·
Steve Chan

Published online: 15 March 2008
© Springer Science+Business Media, LLC. 2008

Erratum to: Breast Cancer Res Treat
DOI 10.1007/s10549-007-9860-9

Unfortunately a mistake was introduced in Table 4. Please find below the correct table.

The online version of the original article can be found under
doi:[10.1007/s10549-007-9860-9](https://doi.org/10.1007/s10549-007-9860-9).

J. P. Crown (✉)
St. Vincent's University Hospital, Dublin, Ireland
e-mail: john.crown@icorg.ie

H. A. Burris III · S. Jones
Sarah Cannon Research Institute, Nashville, TN, USA

F. Boyle
Mater Hospital, Sydney, Australia

M. Koehler · B. O. Newstat · A. Preston · J. Byrne
GlaxoSmithKline, Collegeville, PA, USA

R. Parikh · C. Oliva
GlaxoSmithKline, Uxbridge, Middlesex, UK

S. Chan
City Hospital, Nottingham, UK

Table 4 Maximum toxicity of diarrhea events

	CTC grade (%)									
	Patients (N)		Lapatinib				No lapatinib			
	L	No L	All	G1/2	G3	G4	All	G1/2	G3	G4
<i>Pooled analysis</i>										
All studies	1,417	676	54	45	9	<1	24	20	4	0
Breast	936	477	58	46	11.1	<1	31	26	5	0
Other solid tumors	481	199	48	44	4	<1	6	5	1	0
Lapatinib monotherapy	926	N/A	51	45	6	<1	N/A	N/A	N/A	N/A
Lapatinib + capecitabine ^a	198	191	65	51	13	1	40	30	10	0
<i>Taxane analysis</i>										
Lapatinib + taxanes ^b	401	286	48	39	9	<1	26	24	1	0

No lapatinib is monotherapy with either hormones ($n = 197$), capecitabine ($n = 191$), or paclitaxel ($n = 286$)

CTC, Common toxicity criteria

^a EGF100151

^b EGF10009, EGF10021, and EGF30001